ARVN — Arvinas, Inc.

Summary of Arvinas Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of the end of Q2 2026, Arvinas reported $567.9 million in cash, cash equivalents, and marketable securities, down from $685.4 million at the end of 2025.
• Revenue: Total revenue for the quarter was $249.7 million, driven by:
  • $62.5 million from a licensing agreement with Rigel Pharmaceuticals.
  • $50 million milestone from Pfizer related to the approval of VEPPANU.
  • The recognition of deferred revenue from the Pfizer collaboration agreement, which resulted in a net revenue of $126.4 million.
• Expenses:
  • R&D expenses decreased to $52.6 million from $68.6 million year-over-year.
  • General and administrative expenses were $24 million, slightly down from $25.3 million in Q2 2025.
• Future Guidance: The company maintains a cash runway into the second half of 2028, supporting ongoing development of its pipeline.

2. Strategic Updates and Business Highlights

• FDA Approval: Achieved first-ever FDA approval for VEPPANU, a PROTAC degrader, and completed an out-licensing agreement with Rigel Pharmaceuticals.
• Pipeline Focus: Shifted focus to advancing Phase I clinical programs, particularly:
  • ARV-393: BCL6 degrader showing promise in treating B and T-cell lymphomas, with initial Phase I data expected by the end of 2026.
  • ARV-027: Targeting spinal and bulbar muscular atrophy (SBMA), currently in Phase I trials with initial data anticipated in the first half of 2027.
  • ARV-102: LRRK2 degrader for neurodegenerative diseases, with ongoing regulatory interactions and plans for trials in 2027.

3. Forward Guidance and Outlook

• Clinical Milestones: Anticipated data releases for ARV-393 and ARV-027 in 2026 and 2027, respectively. The company is optimistic about the potential of these programs to address significant unmet medical needs.
• Regulatory Pathways: Plans to initiate clinical trials for ARV-102 in PSP (Progressive Supranuclear Palsy) in 2027, following ongoing regulatory discussions.

4. Bad News, Challenges, or Points of Concern

• Enrollment Challenges: Slow enrollment in the ARV-393 trial due to initial subtherapeutic dosing and competition from existing therapies in the NHL space.
• Regulatory Delays: Clinical hold on the initiation of ARV-102 trials in the U.S. due to additional information requests from the FDA, pushing timelines into 2027.
• Market Competition: The failure of competitors' LRRK2 inhibitors raises questions about the viability of the LRRK2 approach, although Arvinas believes its degrader strategy may offer advantages.

5. Notable Q&A Insights

• ARV-393 Development Path: Management indicated potential for pivotal trials in earlier treatment lines, contingent on upcoming data and efficacy signals.
• ARV-102 Target Population: While focusing on Richardson syndrome patients, the trial may include a broader PSP population, enhancing the potential patient pool.
• HPK1 Degrader Program: Expected to enroll patients with similar tumor types as seen with existing HPK1 inhibitors, with PD-1 likely as the initial combination partner.
• Biomarker Data: Upcoming biomarker data for ARV-102 in October 2026 will be crucial for understanding its potential efficacy in neurodegenerative diseases.

Overall, Arvinas is positioned for growth with a strong pipeline and strategic focus, despite facing challenges in clinical development and regulatory processes.